Discussion
In a new study using mice, onasemnogene abeparvovec, sold as Zolgensma and Itvisma — two approved gene therapies for spinal muscular atrophy (SMA) — did not cause notable issues in reproductive cells, fertility, or embryonic development. Indeed, the preclinical study found no evidence of reproductive harm due…